Glycan Markers of Pluripotent Stem Cells.

Tomoko Watanabe, Hiroaki Tateno

Abstract readReview

In one paragraph

Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tomoko WatanabeMulticellular System Regulation Research Group, Cellular and Molecular Biotechnology Research Institute, Department of Life Science and Biotechnology, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, Japan. watanabe.t@aist.go.jp.

Hiroaki TatenoMulticellular System Regulation Research Group, Cellular and Molecular Biotechnology Research Institute, Department of Life Science and Biotechnology, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pluripotent stem cells (PSCs) are a unique population of cells, capable of infinite self-renewal and differentiation into many cell types, making them essential for regenerative medicine, tissue engineering, and drug discovery. With the increasing use of PSCs in clinical trials, it is crucial to accurately assess their differentiation status and understand the diversity within PSC populations. Glycan markers have emerged as key tools for evaluating the undifferentiated state of PSCs, as well as for live and fixed imaging, and for isolating particular cell populations by applying approaches such as fluorescence-activated cell sorting (FACS). This article summarizes the glycan markers used to assess the undifferentiated states of both mouse and human PSCs, which include embryonal carcinoma cells (ECCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs). By offering a summary of these markers, we aim to advance our understanding of their role in PSC biology, facilitating further developments in stem cell research and broadening medical applications.

Indexed as

Induced Pluripotent Stem CellsPluripotent Stem CellsPolysaccharidesAnimalsBiomarkersCell DifferentiationEmbryonal Carcinoma Stem CellsEmbryonic Stem CellsFlow CytometryHumansMiceBiomarkersPolysaccharidesAntibodyEmbryonic carcinoma cellEmbryonic stem cellGlycan antigenGlycan markerInduced pluripotent stem cellLectinPluripotent stem cell

Identifiers

PMID41917402

DOI10.1007/s10120-022-01312-x

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.